Darin K Edwards Selected Research

2019-nCoV Vaccine mRNA-1273

5/2024	Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
1/2023	Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2.
1/2023	Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
11/2022	Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2.
11/2022	Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
10/2022	A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
3/2022	Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
2/2022	Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.
1/2022	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
1/2022	mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darin K Edwards Research Topics

Disease

21	COVID-19 02/2024 - 10/2020
16	Infections 05/2024 - 05/2021
6	Inflammation (Inflammations) 01/2023 - 10/2020
4	Breakthrough Infections 02/2022 - 08/2021
4	Weight Loss (Weight Reduction) 02/2022 - 08/2021
2	Severe Acute Respiratory Syndrome 03/2022 - 10/2021
2	Pneumonia (Pneumonitis) 02/2022 - 08/2021
2	Human Influenza (Influenza) 01/2022 - 01/2017
1	Virus Diseases (Viral Diseases) 01/2023
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Acute Lung Injury 10/2021
1	Persistent Infection 01/2021

Drug/Important Bio-Agent (IBA)

25	VaccinesIBA 05/2024 - 01/2017
19	2019-nCoV Vaccine mRNA-1273IBA 05/2024 - 10/2020
10	mRNA VaccinesIBA 01/2024 - 01/2017
7	Messenger RNA (mRNA)IBA 01/2024 - 01/2017
5	Neutralizing AntibodiesIBA 11/2022 - 10/2020
3	COVID-19 VaccinesIBA 05/2024 - 10/2021
3	Proteins (Proteins, Gene)FDA Link 01/2024 - 02/2022
3	AntibodiesIBA 01/2023 - 10/2021
2	IgG Receptors (Fc gamma RI)IBA 01/2023 - 11/2022
2	Combined VaccinesIBA 11/2022 - 09/2022
2	N-(2-cyanoethylene)urea (BA 1)IBA 10/2022 - 01/2022
2	Viral AntigensIBA 05/2021 - 01/2021
1	Broadly Neutralizing AntibodiesIBA 05/2024
1	Interleukin-10 (Interleukin 10)IBA 01/2024
1	mRNA-1273.214 COVID-19 vaccineIBA 10/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	CytokinesIBA 01/2022
1	Ad26COVS1IBA 01/2022
1	aluminum sulfate (alum)IBA 10/2021
1	Protein Subunit VaccinesIBA 10/2021
1	AntigensIBA 10/2020
1	Hemagglutinins (Hemagglutinin)IBA 01/2017